Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
CRMD · against 427 other Healthcare companies of similar size
Ranked #19 of 428 · scores higher than 94% of peers
Bars: peers in each 10-point band of the valuation score55 peers with a valuation score of 90–100, including CRMD · Click a bar to see the companies
Mainly thanks to its free cash flow yield, earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | CRMD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 414 reported | 36.9% | 0.1% | 99% | 30% | |
| EBITDA yieldHigher is better · 433 reported | 81.0% | 3.0% | 99% | 50% | |
| Free cash flow yieldHigher is better · 198 reported | 57.8% | -7.9% | 99% | 20% | |
| Book yieldHigher is better · 424 reported | 106.7% | 49.7% | 84% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 6.50T IDR (≈$403M) | 99 | 69 | |
| 19 | 3.8B HKD (≈$486M) | 96 | 56 | |
| 19 | 72.6B JPY (≈$494M) | 96 | 58 | |
| 19 | 44.2B JPY (≈$301M) | 96 | 64 | |
| 19 | 595M USD | 96 | 97 | |
| 19 | 433M USD | 96 | 81 | |
| 19 | 289M USD | 96 | 57 | |
| 19 | 810M USD | 96 | 69 | |
| 19 | 578M USD | 96 | 73 | |
| 19 | 1.3B BRL (≈$238M) | 96 | 77 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score